Literature DB >> 9840909

Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators.

J M Soucie1, B Evatt, D Jackson.   

Abstract

An active surveillance system was used to identify all residents with hemophilia in six U.S. states (Colorado, Georgia, Louisiana, Massachusetts, New York, and Oklahoma). A hemophilia case was defined as a person with physician-diagnosed hemophilia A or B and/or a measured baseline factor VIII or IX activity (FA) of 30% or less. Case-finding methods included patient reports from physicians, clinical laboratories, hospitals, and hemophilia treatment centers. Once identified, trained data abstractors collected clinical and outcome data retrospectively from medical records. Among cases identified in 1993-1995, 2,743 were residents of the six states in 1994, of whom 2,156 (79%) had hemophilia A. Of those with available FA measurements, 1,140 (43%) had severe (FA < 1%), 684 (26%) had moderate (FA 1%-5%), and 848 (31%) had mild (FA 6%-30%) disease. The mean and median age was 25.4 and 23 years, respectively. The age-adjusted prevalence of hemophilia in all six states in 1994 was 13.4 cases/100,000 males (10.5 for hemophilia A and 2.9 for B). The prevalence by race/ethnicity was 13.2 cases/100,000 among white, 11.0 among African American, and 11.5 among Hispanic males. Application of age-specific prevalence rates from the six surveillance states to the U.S. population resulted in an estimated national population of 13,320 cases of hemophilia A and 3,640 cases of hemophilia B. For the 10-year period 1982-1991, the average incidence of hemophilia A and B in the hemophilia surveillance system (HSS) states was estimated to be 1 in 5,032 live male births.

Entities:  

Mesh:

Year:  1998        PMID: 9840909     DOI: 10.1002/(sici)1096-8652(199812)59:4<288::aid-ajh4>3.0.co;2-i

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  63 in total

1.  Public health surveillance and data collection: general principles and impact on hemophilia care.

Authors:  J Michael Soucie
Journal:  Hematology       Date:  2012-04       Impact factor: 2.269

2.  Utility of multiplex ligation-dependent probe amplification (MLPA) for hemophilia mutation screening.

Authors:  A B Payne; C J Bean; W C Hooper; C H Miller
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

3.  Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.

Authors:  Alessandra Rocca; Simona Pizzinelli; Emily Oliovecchio; Elena Santagostino; Angiola Rocino; Alfonso Iorio
Journal:  Blood Transfus       Date:  2010-04-30       Impact factor: 3.443

4.  Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A.

Authors:  Julie Tarrant; Matthew Cormier; Kate Nesbitt; Courtney Dwyer; Christine Hough; David Lillicrap
Journal:  Blood Adv       Date:  2020-06-23

5.  Accommodating chromosome inversions in linkage analysis.

Authors:  Gary K Chen; Erin Slaten; Roel A Ophoff; Kenneth Lange
Journal:  Am J Hum Genet       Date:  2006-06-06       Impact factor: 11.025

6.  Knowledge, attitudes, and behaviors of youths in the US hemophilia population: results of a national survey.

Authors:  Ann-Marie Nazzaro; Sally Owens; W Keith Hoots; Kelly L Larson
Journal:  Am J Public Health       Date:  2006-07-27       Impact factor: 9.308

7.  Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.

Authors:  Lusine Abrahamyan; Andrew R Willan; Joseph Beyene; Marjorie Mclimont; Victor Blanchette; Brian M Feldman
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

8.  Long-term phenotypic correction in factor IX knockout mice by using ΦC31 integrase-mediated gene therapy.

Authors:  A Keravala; C L Chavez; G Hu; L E Woodard; P E Monahan; M P Calos
Journal:  Gene Ther       Date:  2011-03-17       Impact factor: 5.250

Review 9.  Adeno-associated viral vectors for the treatment of hemophilia.

Authors:  Katherine A High; Xavier M Anguela
Journal:  Hum Mol Genet       Date:  2015-11-27       Impact factor: 6.150

10.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.